Morphic Appoints ArQule’s Schegerin Chief Financial, Operating Officer

Morphic Therapeutic (NASDAQ: [[ticker:MORF]]) has named Marc Schegerin as its chief financial officer and chief operating officer. Schegerin was most recently CFO at cancer drug developer ArQule, which Merck (NYSE: [[ticker:MRK]]) agreed to acquire in December for $2.7 billion. Schegerin joins another recent addition to Morphic’s C suite, Peter Linde, who joined the company in March as chief medical officer.

Schegerin’s prior experience includes healthcare investment banking roles at CitiGroup (NYSE: [[ticker:C]]) and Bank of America Merrill Lynch (NYSE: [[ticker:BAC]]) and industry management roles at Biogen (NASDAQ: [[ticker:BIIB]]) and Sage Therapeutics (NASDAQ: [[ticker:SAGE]]). Waltham, MA-based Morphic raised $80 million in September 2018 to move its investigational oral medicines for chronic diseases into the clinic. The biotech’s drug candidates target a family of proteins on the surface of cells called integrins.

Author: Sarah de Crescenzo

Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register. She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.